Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2011
At a glance
- Drugs Bremelanotide (Primary)
- Indications Female sexual dysfunction; Menopause
- Focus Adverse reactions; Therapeutic Use
- Sponsors Palatin Technologies
- 27 Sep 2007 Primary endpoint met; top-line results reported in a Palatin media release.
- 27 Sep 2007 Status changed from in progress to completed.
- 27 Feb 2007 Interim results have been reported.